Royalty Pharma (RPRX) Cash from Operations (2019 - 2026)
Royalty Pharma (RPRX) posted Cash from Operations of 718233000.0 for Q1 2026, down 13.17% sequentially from 827148000.0 in Q4 2025, and up 20.49% YoY from 596076000.0 in Q1 2025.
Royalty Pharma (RPRX) Cash from Operations (2019 - 2026) Analysis & Trends
Royalty Pharma has reported Cash from Operations for 8 years, with the latest figure at 718233000.0 in Q1 2026.
- Quarterly Cash from Operations rose 20.49% year-over-year to 718233000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 2611980000.0 (down 3.28% YoY) and the FY2025 annual result came in at 2489823000.0, down 10.08% from the prior year.
- Cash from Operations slipped to 718233000.0 in Q1 2026 per RPRX's latest filing, from 827148000.0 in the prior quarter.
- Over five years, Cash from Operations peaked at 1033837000.0 in Q1 2023 and troughed at 363984000.0 in Q2 2025.
- A 5-year average of 653460235.29 and a median of 658209000.0 in 2024 frame the typical range for Cash from Operations.
- The sharpest annual moves came in 2023 and 2025: Cash from Operations soared 124.62% in 2023, then slumped 44.7% in 2025.
- Over 5 years, Cash from Operations stood at 569931000.0 in 2022, then soared by 35.57% to 772628000.0 in 2023, then retreated by 3.9% to 742525000.0 in 2024, then grew by 11.4% to 827148000.0 in 2025, then fell by 13.17% to 718233000.0 in 2026.
- According to Business Quant data, Cash from Operations over the past three periods registered 718233000.0, 827148000.0, and 702615000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -387.32 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 462.82 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -1.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 728.46 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 326.72 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -88.83 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | -270.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 728.46 Mn |
| Jun 30, 2026 | 728.46 Mn |
| Mar 31, 2026 | 718.23 Mn |
| Mar 31, 2026 | 718.23 Mn |
| Dec 31, 2025 | 827.15 Mn |
| Dec 31, 2025 | 827.15 Mn |
| Sep 30, 2025 | 702.62 Mn |
| Sep 30, 2025 | 702.62 Mn |
| Jun 30, 2025 | 363.98 Mn |
| Jun 30, 2025 | 363.98 Mn |
| Mar 31, 2025 | 596.08 Mn |
| Mar 31, 2025 | 596.08 Mn |
| Dec 31, 2024 | 742.53 Mn |
| Dec 31, 2024 | 742.53 Mn |
| Sep 30, 2024 | 703.61 Mn |
| Sep 30, 2024 | 703.61 Mn |
| Jun 30, 2024 | 658.21 Mn |
| Jun 30, 2024 | 658.21 Mn |
| Mar 31, 2024 | 664.64 Mn |
| Mar 31, 2024 | 664.64 Mn |